Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exubera Reimbursement Plan May Focus On Outcomes Relative To Oral Agents

Executive Summary

Pfizer's strategy for securing reimbursement for Exubera could focus on the inhaled insulin's benefits on overall healthcare outcomes relative to oral diabetes therapies

You may also be interested in...



Diabetes Drugs Under Part D: Pfizer Exubera Slow To Gain Formulary Traction

Pfizer's inhaled insulin Exubera is not being covered by many national Part D plans, and plans that do cover Exubera put it on higher copay tiers and require patients to obtain authorization before getting it, an analysis of 2007 Part D plan coverage of diabetes medications by F-D-C Reports' Medicare Drug Focus shows

Diabetes Drugs Under Part D: Pfizer Exubera Slow To Gain Formulary Traction

Pfizer's inhaled insulin Exubera is not being covered by many national Part D plans, and plans that do cover Exubera put it on higher copay tiers and require patients to obtain authorization before getting it, an analysis of 2007 Part D plan coverage of diabetes medications by F-D-C Reports' Medicare Drug Focus shows

Pfizer Predicts Exubera, Chantix Favorable Reimbursement Despite Delays

Pfizer's Chantix and Exubera are being favorably received by payers in early formulary discussions, Senior VP-Global Pharmaceutical Finance Peter Brandt said during the company's second quarter earnings call July 20

Related Content

UsernamePublicRestriction

Register

PS046857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel